Logo

Exelixis In-Licenses Second Anti-Cancer Compound from Aurigene Following the US FDA's Acceptance of IND for P-I Study of XL114 in Non-Hodgkin's Lymphoma

Share this

Exelixis In-Licenses Second Anti-Cancer Compound from Aurigene Following the US FDA's Acceptance of IND for P-I Study of XL114 in Non-Hodgkin's Lymphoma

Shots:

  • Exelixis has exercised its exclusive option under the companies’ July 2019 agreement to in-license XL114 (formerly AUR104)- following the US FDA’s IND acceptance for P-I study in NHL
  • Exelixis has assumed responsibility for the future clinical development- commercialization and global manufacturing of XL114. By exercising the option for XL114- Aurigene received $10M as option exercise payment
  • Exelixis previously exercised its option to in-license XL102 from Aurigene in Dec 2020 and initiated a P-I trial of XL102 as a single agent and in combination with other anti-cancer agents in patients with advanced or metastatic solid tumors in Jan 2021

Ref: Businesswire | Image: Twitter

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions